Published online 15 December 2021 *Nucleic Acids Research, 2022, Vol. 50, No. 1* ***599–600***
https://doi.org/10.1093/nar/gkab1266

Erratum

Correction to 'The double-stranded RNA-binding protein, Staufen1, is an IRES-transacting factor regulating HIV-1 cap-independent translation initiation'

Hade Ramos[1], Anne Monette[2], Meijuan Niu[2], Aldo Barrera[1], Brenda López-Ulloa[1], Yazmín Fuentes[1], Paola Guizar[2,4], Karla Pino[1], Luc DesGroseillers[3], Andrew J. Mouland[2,4] and Marcelo López-Lastra[1,*]

[1]Laboratorio de Virología Molecular, Instituto Milenio de Inmunología e Inmunoterapia, Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, Escuela de Medicina, Pontificia Universidad Catóolica de Chile, Marcoleta 391, Santiago, Chile, [2]HIV-1 RNA Trafficking Laboratory, Lady Davis Institute at the Jewish General Hospital, Montréal, Québec H3T 1E2, Canada, [3]Department of Biochemistry and Molecular Medicine, University of Montreal, P.O. Box 6128, Station Centre Ville, Montreal, Québec H3C 3J7, Canada and [4]Department of Medicine, McGill University, Montréal, Québec H4A 3J1, Canada

Errors were introduced in Figure 3 during production of the article (1). The X-axis of Figure 3D should be ΔSV40 not SV40. The publisher apologises for these errors and wishes to correct Figure 3 as shown below.

The published article has been updated. These corrections do not affect the results, discussion and conclusions presented in the article.

REFERENCES

1. Ramos,H., Monette,A., Niu,M., Barrera,A., López-Ulloa,B., Fuentes,Y., Guizar,P., Pino,K., DesGroseillers,L., Mouland,A.J. *et al.* (2021) Marcelo López-Lastra, The double-stranded RNA-binding protein, Staufen1, is an IRES-transacting factor regulating HIV-1 cap-independent translation initiation, *Nucleic Acids Res.*, https://doi.org/10.1093/nar/gkab1188.

*To whom correspondence should be addressed. Tel: +1 56 22 354 3410; Email: malopez@med.puc.cl



Figure 3. Staufen1 does not enhance alternative splicing of the dl HIV-1 IRES RNA nor increases the cryptic promoter activity of the dl HIV-1 DNA. (**A**, **B**) The dl HIV-1 IRES (150 ng) was cotransfected with a control scRNA (100 nM) or with siRLuc (100 nM), in the presence, or the absence (−), of the Stau155-HA3 (325 ng) plasmid. (**A**) Schematic representation of the dl reporter targeted by the siRNA RLuc (siRLuc) targeting the Renilla luciferase ORF (upper panel). Total protein extracts were prepared 48 hrs post-transfection. The expression of Stau155-HA3 was determined by western blot, using the GAPDHprotein as a loading control (lower panel). (**B**) RLuc and FLuc activities were measured and expressed relative to the values obtained with scRNA, set to 100% (RLA). Values shown are the mean (±SEM) for six independent experiments, each performed in duplicate. Statistical analysis was performed by an ordinary two-way ANOVA test (*$P < 0.01$; ns, not significant). (**C**, **D**) HEK 293T cells were transfected with either the dl HIV-1 IRES (150 ng) or a promoterless ΔSV40-dl HIV-1 IRES (150 ng) vector in the presence, or the absence (−), of the Stau155-HA3 (325 ng) plasmid. 24 hrs post-transfection total protein extracts were prepared. (**C**) Schematic representation of the dl HIV-1 IRES and ΔSV40-dl HIV-1 IRES plasmids (upper panel). The expression of Stau155-HA3 was determined by western blot, using the GAPDH protein as a loading control (lower panel). (**D**) RLuc and FLuc activities were measured, and results are expressed as RLA relative to the activities obtained from the dl HIV-1 IRES vector when in the absence of the Stau155-HA3, set to 100%. Values shown in are the mean (±SEM) for three independent experiments, each performed in duplicate. Statistical analysis was performed by an ordinary two-way ANOVA test (**** $P < 0.0001$; ns, not significant).